Chuangyebang learned that recently, Suzhou Yuce Biotechnology Co., Ltd. announced the completion of nearly 100 million yuan in Series A financing, led by Boyuan Capital, followed by Jianyi (formerly Sinopharm) Capital, and the old shareholder Puhua Capital and well-known industrial capital continued to increase Note. This round of financing will help Yuce Bio to create a closed loop of the clinical transformation industry chain of new biomarkers, and promote the in-depth development of hypersensitive biomarker detection technology and the clinical transformation process of new biomarkers.
The single-molecule immunoassay technology owned by Yuce Bio has completely independent intellectual property rights, and the innovative technology path has the advantages of high throughput, good stability, and easy mass production, making the clinical transformation of single-molecule immunoassay technology possible. So far, the core single-molecule immunoassay equipment product line of Yuce Bio has fully covered scientific research and clinical needs such as semi-automatic, fully automatic, ultra-sensitive, high-throughput, etc. The kit production line covers nerves, infectious diseases, tumors, myocardium, inflammation and other application fields, forming a solid product barrier.
Through the integration of industrial resources, Yuce Bio has also achieved key layouts in the fields of upstream core raw materials and molecular-aided diagnosis. Recently, Yucheck Biotech obtained the first domestic medical device approval for fully automatic single-molecule immunodiagnosis equipment, indicating that the company has fully taken the lead in the segmented track in the field of single-molecule immunodiagnosis.
The sensitivity of single-molecule immunoassay technology is 1000 times higher than that of traditional immunoassay technology, and it is considered to be the next generation immunoassay technology after chemiluminescence technology. The significant improvement in sensitivity makes it possible to apply nearly a thousand biomarkers that are difficult to achieve clinical translation by traditional immunodetection technologies in the clinical field. With single-molecule immunoassay technology as the core, Yuce Bio is committed to creating a complete commercial closed loop from new biomarker screening, core raw material research and development, development of hypersensitive biomarker detection kits to clinical transformation, and promotes the development of hypersensitive new biomarkers. Clinical translation application.
Li Han, vice president of Boyuan Capital Investment, said: I am very happy to lead the A round of financing in Yuce Bio. Single-molecule immunoassay technology has a sensitivity far exceeding that of traditional immunoassay technology, and is a very important tool for the development and clinical translation of many low-abundance biomarkers. The single-molecule immunodetection technology platform of Yuce Bio has completely independent intellectual property rights, which fills the gap in the domestic hypersensitivity detection field. The ease of use of the platform is very suitable for neurodegenerative diseases, ophthalmology, nephrology, infection and other diseases. , clinical translation of multiple types of new markers.
Zou Min, partner of Jianyi Capital, said: Yuce Bio is in line with our investment strategy of “clinical + life science tools” in the IVD field. Based on the innovative technology route of single-molecule immunization, the company has established its own leading advantages in scientific research and clinical direction. Especially in the field of neuroscience, it has achieved the independent control of upstream antibody raw materials, and with the molecular diagnosis platform, it can provide a more complete diagnosis plan for the clinic.
Zhou Mi, managing partner of PricewaterhouseCoopers, said: Yuce Bio is very in line with our investment philosophy of “translational medicine”. We believe that the core proposition of medical device venture capital is the clinical transformation and commercial transformation of intellectual property or scientific and technological achievements. Medical device transformation requires “” Industry-university-research-medical-government “five-in-one is closely coordinated, and venture capital institutions and government departments are the important driving forces behind it. The single-molecule immunoassay technology with independent intellectual property rights has obvious advantages and strong clinical transformation capabilities. The new biomarker transformation platform with single-molecule immunoassay technology as the core will have the opportunity to promote a large number of biomarkers “industry-university-research-medical administration” true transformation.
Guan Zhichao, founder of Yuce Bio, said: Thank you for the support of this round of investors and all shareholders of Yuce Bio. We will continue to forge ahead and set sail on the road of more specialized and ambitious scientific research and clinical practice, and strive to become a supporter and leader in the field of life and health trusted by customers.
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Yioutou China Net Venture State Investment Community
This article is reprinted from: https://readhub.cn/topic/8heFEMovsiC
This site is for inclusion only, and the copyright belongs to the original author.